- Evelo Biosciences seeks to harass the ability of microbes in the gut to direct the immune system.
- The approach is novel and unproven and thus investing is a very high risk proposition.
- If efficacious, these are benign, inexpensive to manufacture products which can provide treatments in large markets such as atopic dermatitis, psoriasis and COVID-19.
- Positive data readouts will validate the platform and may move the stock price significantly upward. If data reads out poorly, expect a free fall.
For further details see:
Evelo Biosciences: Clinical Data Coming Soon